摘要
口腔颌面-头颈部恶性肿瘤发病率位居人类恶性肿瘤的第6位,大部分患者就诊时已到局部晚期阶段,经过手术、放化疗后仍有很高比例的患者会发生局部复发和/或远处转移。针对复发和/或转移性口腔颌面-头颈部鳞癌患者,以EGFR靶向治疗药物为基础的靶向化疗是目前一线治疗常规应用方案。国际上已批准的治疗头颈部肿瘤的靶向药物有尼妥珠单克隆抗体(单克隆抗体,以下简称单抗)和西妥昔单抗,目前西妥昔单抗的指南很多,而尼妥珠单抗在口腔颌面-头颈部恶性肿瘤的应用尚无明确规范。本文结合文献及相关专家的经验,制定专家共识,对尼妥珠单抗的抗肿瘤机制以及目前临床应用情况进行阐述,制定了尼妥珠单抗治疗口腔颌面-头颈部鳞癌的建议方案,供临床医师参考。
The incidence of malignant tumors in oro-maxillofacial regions and head and neck is at the sixth place of human malignant tumors.Most of the patients have reached the local advanced stage when they are treated.After surgery and radiotherapy,a large proportion of the patients may have local recurrence and/or distant metastasis.For patients with recurrent and/or metastatic oro-maxillofacial squamous cell carcinoma of oro-maxillofacial or head and neck,targeted chemotherapy based on EGFR targeted drugs is the conventional first-line treatment.Currently,nimotuzumab and cetuximab have been approved as the targeted drugs for the treatment of head and neck tumors in the world.There are many guidelines for cetuximab,but there is no clear standard for the application of nimotuzumab in oro-maxillofacial head and neck cancer.Therefore,in this paper,combined the reference documents with the experience of relevant experts,the expert consensus was established,and the anti-tumor mechanism and current clinical application of nimotuzumab were elaborated,and the recommended scheme of nimotuzumab in the treatment of oro-maxillofacial region and head and neck squamous cell carcinoma was formulated for clinicians'reference.
作者
郭伟
孙沫逸
冉炜
唐瞻贵
李龙江
孙志军
孟箭
郑家伟
尚伟
杨凯
龚忠诚
武和明
席庆
谢卫红
孔琳
鞠侯雨
任国欣
GUO Wei;SUN Moyi;RAN Wei;TANG Zhangui;LI Longjiang;SUN Zhijun;MENG Jian;ZHENG Jiawei;SHANG Wei;YANG Kai;GONG Zhongcheng;WU Heming;XI Qing;XIE Weihong;KONG Lin;JU Houyu;REN Guoxin(Department of Oral Maxillofacial-Head and Neck Oncology,Ninth People's Hospital affiliated to Shanghai Jiao Tong University School of Medicine,China,200011;Department of Oral and Maxillofacial Surgery,School of Stomatology,The Fourth Military Medical University,Xi'an;The First Affiliated Hospital of Sun Yat sen University;Central South University School,Xiangya School of Stomatology;West China School of Stomatology,Sichuan University;Department of Oral Maxillofacial Surgery,Stomatological Hospital of Wuhan University;Department of Stomatology,Xuzhou Central Hospital;Department of Oral Maxillofacial Surgery,Affiliated Hospital of Qingdao University;Department of Oral Maxillofacial Surgery,First Affiliated Hospital of Chongqing Medical University;Department of Oral Maxillofacial Surgery,First Affiliated Hospital of Xinjiang Medical University;Department of Oral Maxillofacial Surgery,Stomatological College of Nanjing Medical University;Department of Stomatology,Chinese PLA General Hospital,Beijing;Department of Oral Maxillofacial Surgery,First Affiliated Hospital of Zhengzhou University;Shanghai Proton Heavy Ion Hospital)
出处
《实用口腔医学杂志》
CAS
CSCD
北大核心
2021年第4期445-450,共6页
Journal of Practical Stomatology
